Alpha-lipoic acid in non-proliferative diabetic retinopathy treatment
https://doi.org/10.14341/2072-0351-5823
Abstract
Aim.
The aim of this study is to assess the therapeutic efficacy of alpha-lipoic acid in patients with type 2 diabetes mellitus (DM) and non-proliferativediabetic retinopathy.
Materials and methods.
47 patients with mild to moderate non-proliferative diabetic retinopathy were included in this trial. Dynamics of ophthalmologicparameters were assessed by means of stereoscopic photography of ocular fundus. Patients were examined every 6 months in order to registernew cases of clinically significant macular oedema.
Results.
During 24 months follow-up period, patients treated with 600 mg of alpha-lipoic acid showed stabilization in development of diabetic retinopathy.New cases of macular oedema, as well as transition into a more severe stage of retonopathy were less common in those patients. Vision andcontrast sensation also remained stable in the majority of participants from experimental group.Conclusions. 600 mg of alpha-lipoic acid may be recommended for patients with type 2 DM as part of complex therapy
The aim of this study is to assess the therapeutic efficacy of alpha-lipoic acid in patients with type 2 diabetes mellitus (DM) and non-proliferativediabetic retinopathy.
Materials and methods.
47 patients with mild to moderate non-proliferative diabetic retinopathy were included in this trial. Dynamics of ophthalmologicparameters were assessed by means of stereoscopic photography of ocular fundus. Patients were examined every 6 months in order to registernew cases of clinically significant macular oedema.
Results.
During 24 months follow-up period, patients treated with 600 mg of alpha-lipoic acid showed stabilization in development of diabetic retinopathy.New cases of macular oedema, as well as transition into a more severe stage of retonopathy were less common in those patients. Vision andcontrast sensation also remained stable in the majority of participants from experimental group.Conclusions. 600 mg of alpha-lipoic acid may be recommended for patients with type 2 DM as part of complex therapy
About the Authors
Tatiana Yul'evna Demidova
Russian Medical Academy of Postgraduate Education, Moscow
Yulia Alexandrovna Trakhtenberg
Medical Centre "Diagnost", Moscow
References
1. National Diabetes Statistics, 2010. National Diabetes Information Clearinghouse, 2008.
2. Ingerman A., Dewey-Mattia D. Emerging Treatments for Diabetic Macular Edema // Retina Today. - 2010. - Р. 52-54.
3. Балашевич Л.И., Бржеский В.В. и др. Глазные проявления диа- бета // СпбМАПО. - 2004. - С. 123-199.
4. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from srereoscopic color fundus photographs - an extension of the modified Airlie House classificacion. ETDRS Report №10 // Ophthalmology. - 1991. - Vol. 98. - P. 786-806.
5. Chaturvedi N., Porta M., Klein R. et al. Effect of candesartan on prevention (DIRECT-Prevent1) and progression (DIRECT-Protect1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials // Lancet. - 2008. - № 372. - Р. 1394-1402.
6. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes // N. Engl. J. Med. - 2010. - № 363. - Р. 233-244.
7. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate //Am. J. Cardiol. - 2008. - 102(12A). - 34L-40L.
8. Yilmaz T., Weaver C.D., Gallagher M.J. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review // Ophthalmology. - 2009. - № 116(5). - Р. 902-911.
9. Haller J.A., Kuppermann B.D., Blumenkranz M.S. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema // Arch. Ophthalmol. - 2010. - № 128(3). - Р. 289-296.
10. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. - 2010. - № 248(7). - Р. 915-930.
11. Donnelly R. Vascular complications of diabetes // Blackwell Publishing. - 2005. - P. 189-213.
12. Балаболкин М.И., Креминская В.М., Клебанова Е.М. Роль окисли- тельного стресса в патогенезе диабетической нейропатии и возможность его коррекции препаратами -липоевой кислоты // Проблемы эндокринологии. - 2005. - Т. 51, № 3. - С. 22-32.
13. Reljanovic M., Reichel G., Lobisch M. et al. Treatment of diabetic polyneuropathy with the antioxydant thioctic acid (alfa-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II) Alfa-lipoic acid in diabetic neuropathy // Free Radical Reseach. - 1999. -Vol. 31, P. 171-179.
14. Ziegler D., Hanefild M., Ruhnau K. et al. The ALADIN III Study Group. Treatment of symptomatic diabetic polyneuropathy with the antioxydant alfa-lipoic acid. A 3 week multicenter randomized controlled trial // Diabetes Care. - 1999. - Vol. 22, P. 1296-1301.
15. Дедов И.И., Удовиченко О.В., Галстян Г.Р. Диабетическая стопа. - М.: Практическая медицина. - 2005. - С. 48.
16. Morcos M., Borcea V., Isermann B. et al. Effect of -lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus // Diab. Res. Clin. Pract. - 2001. - Vol. 52. - P. 175-183.
Review
For citations:
Demidova T.Yu., Trakhtenberg Yu.A. Alpha-lipoic acid in non-proliferative diabetic retinopathy treatment. Diabetes mellitus. 2011;14(4):82-86. (In Russ.) https://doi.org/10.14341/2072-0351-5823
Views:
15590
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
